Gritstone to Participate in Cowen 42nd Annual Health Care Conference
Gritstone bio, a clinical-stage biotechnology company (Nasdaq: GRTS), announced that CEO Andrew Allen will participate in the "Infectious Disease" panel at the Cowen 42nd Annual Health Care Conference virtually from March 7-9, 2022. The panel is scheduled for March 9 from 10:30 to 11:30 a.m. ET. A live webcast will be available on the company's website, with an archived replay accessible for 30 days post-event. Gritstone bio focuses on innovative immunotherapies for cancer and infectious diseases, leveraging machine learning technology to develop targeted treatments.
- None.
- None.
EMERYVILLE, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that Andrew Allen, M.D., Ph.D., Co-founder, President and Chief Executive Officer will participate in the “Infectious Disease” panel at the Cowen 42nd Annual Health Care Conference, which is being held virtually from March 7 to 9.
Panel Details
Title: Infectious Disease
Date and Time: Wednesday, March 9th from 10:30 – 11:30 a.m. ET
A live webcast of the panel will be accessible via the Investors & Media section of the company’s website at https://ir.gritstonebio.com/investors/events. An archived replay will be accessible for 30 days following the event.
About Gritstone bio
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. Gritstone develops its products by leveraging two key pillars—first, a proprietary machine learning-based platform, Gritstone EDGE™, which is designed to predict antigens that are presented on the surface of cells, such as tumor or virally-infected cells, that can be seen by the immune system; and, second, the ability to develop and manufacture potent immunotherapies utilizing these antigens to potentially drive the patient’s immune system to specifically attack and destroy disease-causing cells. The company’s lead oncology programs include an individualized neoantigen-based immunotherapy, GRANITE, and an “off-the-shelf” shared neoantigen-based immunotherapy, SLATE, which are being evaluated in clinical studies. Within its infectious disease pipeline, Gritstone is advancing CORAL, a COVID-19 program to develop a second-generation vaccine, with support from departments within the National Institutes of Health (NIH), the Bill & Melinda Gates Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI) and through a license agreement with La Jolla Institute for Immunology. Additionally, the company has a global collaboration for the development of a therapeutic HIV vaccine with Gilead Sciences. For more information, please visit gritstone.com.
Gritstone Contacts
Media:
Dan Budwick
1AB
(973) 271-6085
dan@1abmedia.com
Investors:
George E. MacDougall
Director, Investor Relations & Corporate Communications
Gritstone bio
Ir@gritstone.com
FAQ
When is Gritstone bio's participation in the Cowen 42nd Annual Health Care Conference?
How can I watch the Gritstone bio conference panel?
What are Gritstone bio's key therapies being developed?
What is the focus of Gritstone bio's infectious disease pipeline?
What collaborations does Gritstone bio have for its HIV vaccine development?
